Lovelace Biomedical, a not-for-profit preclinical contract research organization, has launched and offers toxicology, pharmacology and other services to pharmaceutical and biotechnology companies. It will partner with companies to cost-effectively and efficiently advance preclinical development of therapeutic compounds and novel technologies, with services and expertise spanning the fields of respiratory disease, infectious disease, gene therapy, neuroscience, alternative tobacco products and medical countermeasures, as well as drug discovery and others.

Lovelace Biomedical draws on nearly seven decades of leadership in scientific research experience from the Lovelace family of companies, including the Lovelace Respiratory Research Institute, to utilize a multi-disciplinary toolset to address simple and complex preclinical challenges. Its 500 employees work closely with pharmaceutical and biotechnology companies—providing high-quality research services and achieving results that help advance their products into clinical development. Lovelace Biomedical's services include toxicology, IND-enabling programs, formulation, pharmacology, bioanalytical/analytical chemistry and medicinal chemistry.

"The Lovelace family of companies has a rich history in scientific innovation—from pioneering aviation medicine and work with NASA, to groundbreaking research in respiratory illnesses and infectious diseases," said Robert W. Rubin, Ph.D., president and chief executive officer of the Lovelace Respiratory Research Institute and associated companies. "Today we carry this tradition of scientific excellence through our collaborations with biotechnology and pharmaceutical companies that seek to improve lives by treating devastating diseases and disorders. Our expertise in preclinical research can help these companies answer difficult questions about their therapeutic programs and find the right path forward toward clinical investigation and regulatory approval."

Operating in an expansive bio-secure facility on 100 acres of land with 300,000 square feet of laboratory space, Lovelace Biomedical is capable of handling preclinical activities for nearly any therapeutic program. Its team includes expert toxicologists, chemists, veterinarians, pathologists, pharmacologists, project managers and more.  This diverse team draws on its vast and varied experience to enable development of commercially-viable product candidates, with particular expertise in respiratory disease, gene therapy, infectious disease and neuroscience. In addition to toxicology, Lovelace Biomedical has expertise with a wide variety of large and small animal pharmacology models, as well as over 10,000 square feet of ABSL3-enhanced laboratory space.

Lovelace Biomedical maintains high standards for humane and ethical treatment of animals involved in research. Research facilities are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, Office of Laboratory Animal Welfare and the United States Department of Agriculture.